<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35614165</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>269</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>Creatine kinase and prognosis in amyotrophic lateral sclerosis: a literature review and multi-centre cohort analysis.</ArticleTitle><Pagination><StartPage>5395</StartPage><EndPage>5404</EndPage><MedlinePgn>5395-5404</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-022-11195-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Amyotrophic lateral sclerosis (ALS) is a prognostically heterogeneous neurodegenerative disease. Blood creatine kinase (CK) level has been inconsistently reported as a prognostic biomarker and raised levels in some ALS patients have been presumed to reflect muscle wasting, which is also variable.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">MEDLINE was systematically searched for papers related to CK in ALS and the relevant studies were reviewed. Using data from 222 ALS patients in a multi-centre, prospective, longitudinal cohort, survival analyses using Kaplan-Meier and Cox proportional hazards models were undertaken in relation to CK and other prognostic factors.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-five studies investigating CK in ALS were identified, of which 10 specifically studied the link between CK and survival. Five studies observed no association, four found that higher CK levels were associated with longer survival and one, the opposite. In our cohort (n&#x2009;=&#x2009;222), 39% of patients had a CK level above the laboratory reference range. Levels were higher in males compared to females (p&#x2009;&lt;&#x2009;0.001), in patients with limb versus bulbar onset of symptoms (p&#x2009;&lt;&#x2009;0.001) and in patients with higher lower motor neuron burden (p&#x2009;&lt;&#x2009;0.001). There was no significant trend in longitudinal CK values. Although a higher standardised log (CK) at first visit was associated with longer survival in univariate analysis (hazard ratio 0.75, p&#x2009;=&#x2009;0.003), there was no significant association after adjusting for other prognostic covariates.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">While raised CK levels in ALS do reflect lower motor neuron denervation to a large extent, they are not independently associated with survival when measured in the symptomatic phase of the disease.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Jiali</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, West Wing level 3 / level 6, Oxford, OX3 9DU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dharmadasa</LastName><ForeName>Thanuja</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, West Wing level 3 / level 6, Oxford, OX3 9DU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malaspina</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Neurology, University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Pamela J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talbot</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, West Wing level 3 / level 6, Oxford, OX3 9DU, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, West Wing level 3 / level 6, Oxford, OX3 9DU, UK. martin.turner@ndcn.ox.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Alexander G</ForeName><Initials>AG</Initials><Identifier Source="ORCID">0000-0003-1063-3277</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, West Wing level 3 / level 6, Oxford, OX3 9DU, UK. alexander.thompson@ndcn.ox.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/T006927/1</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>TURNER/OCT18/989-797</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>TURNER/OCT15/972-797</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/S004920/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/T006927/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.3.2</RegistryNumber><NameOfSubstance UI="D003402">Creatine Kinase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003402" MajorTopicYN="N">Creatine Kinase</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biomarker</Keyword><Keyword MajorTopicYN="N">Creatine kinase</Keyword><Keyword MajorTopicYN="N">Motor neuron disease</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>25</Day><Hour>23</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35614165</ArticleId><ArticleId IdType="pmc">PMC9467954</ArticleId><ArticleId IdType="doi">10.1007/s00415-022-11195-8</ArticleId><ArticleId IdType="pii">10.1007/s00415-022-11195-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chi&#xf2; A, Logroscino G, Hardiman O, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10:310&#x2013;323. doi: 10.3109/17482960802566824.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960802566824</ArticleId><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng H-J, Debray TPA, Visser AE, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17:423&#x2013;433. doi: 10.1016/S1474-4422(18)30089-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30089-9</ArticleId><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR. Motor neuron disease: biomarker development for an expanding cerebral syndrome. Clin Med. 2016;16:s60&#x2013;s65. doi: 10.7861/clinmedicine.16-6-s60.</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmedicine.16-6-s60</ArticleId><ArticleId IdType="pmc">PMC6329564</ArticleId><ArticleId IdType="pubmed">27956443</ArticleId></ArticleIdList></Reference><Reference><Citation>Verber NS, Shepheard SR, Sassani M, et al. Biomarkers in motor neuron disease: a state of the art review. Front Neurol. 2019;10:291. doi: 10.3389/fneur.2019.00291.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00291</ArticleId><ArticleId IdType="pmc">PMC6456669</ArticleId><ArticleId IdType="pubmed">31001186</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallimann T, Wyss M, Brdiczka D, et al. Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the &#x201c;phosphocreatine circuit&#x201d; for cellular energy homeostasis. Biochem J. 1992;281:21&#x2013;40. doi: 10.1042/bj2810021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bj2810021</ArticleId><ArticleId IdType="pmc">PMC1130636</ArticleId><ArticleId IdType="pubmed">1731757</ArticleId></ArticleIdList></Reference><Reference><Citation>Moghadam-Kia S, Oddis CV, Aggarwal R. Approach to asymptomatic creatine kinase elevation. Cleve Clin J Med. 2016;83:37&#x2013;42. doi: 10.3949/ccjm.83a.14120.</Citation><ArticleIdList><ArticleId IdType="doi">10.3949/ccjm.83a.14120</ArticleId><ArticleId IdType="pmc">PMC4871266</ArticleId><ArticleId IdType="pubmed">26760521</ArticleId></ArticleIdList></Reference><Reference><Citation>Amrit AN, Anderson MS. Serum creatine phosphokinase in amyotrophic lateral sclerosis. Correlation with sex, duration, and skeletal muscle biopsy. Neurology. 1974;24:834&#x2013;837. doi: 10.1212/wnl.24.9.834.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.24.9.834</ArticleId><ArticleId IdType="pubmed">4859480</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SY, Park JE, Lee YJ, et al. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol. 2013;66:408&#x2013;414. doi: 10.1016/j.jclinepi.2012.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2012.09.016</ArticleId><ArticleId IdType="pubmed">23337781</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson AG, Gray E, Verber N, et al. Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain. Brain Commun. 2022;4:fcac029. doi: 10.1093/braincomms/fcac029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcac029</ArticleId><ArticleId IdType="pmc">PMC8870425</ArticleId><ArticleId IdType="pubmed">35224491</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura F, Fujimura C, Ishida S, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66:265&#x2013;267. doi: 10.1212/01.wnl.0000194316.91908.8a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000194316.91908.8a</ArticleId><ArticleId IdType="pubmed">16434671</ArticleId></ArticleIdList></Reference><Reference><Citation>Boer P. Estimated lean body mass as an index for normalization of body fluid volumes in humans. Am J Physiol. 1984;247:F632&#x2013;636. doi: 10.1152/ajprenal.1984.247.4.F632.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajprenal.1984.247.4.F632</ArticleId><ArticleId IdType="pubmed">6496691</ArticleId></ArticleIdList></Reference><Reference><Citation>van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. J Stat Softw. 2011;45:1&#x2013;67. doi: 10.18637/jss.v045.i03.</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v045.i03</ArticleId></ArticleIdList></Reference><Reference><Citation>White IR, Royston P. Imputing missing covariate values for the Cox model. Stat Med. 2009;28:1982&#x2013;1998. doi: 10.1002/sim.3618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.3618</ArticleId><ArticleId IdType="pmc">PMC2998703</ArticleId><ArticleId IdType="pubmed">19452569</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin DB, Schenker N. Multiple imputation in health-care databases: an overview and some applications. Stat Med. 1991;10:585&#x2013;598. doi: 10.1002/sim.4780100410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.4780100410</ArticleId><ArticleId IdType="pubmed">2057657</ArticleId></ArticleIdList></Reference><Reference><Citation>Lima AF, Evangelista T, de Carvalho M. Increased creatine kinase and spontaneous activity on electromyography, in amyotrophic lateral sclerosis. Electromyogr Clin Neurophysiol. 2003;43:189&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">12712806</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson SB, Kasarskis EJ, Hu N, et al. Relationship of creatine kinase to body composition, disease state, and longevity in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:473&#x2013;477. doi: 10.3109/21678421.2015.1062516.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1062516</ArticleId><ArticleId IdType="pmc">PMC5595062</ArticleId><ArticleId IdType="pubmed">26312548</ArticleId></ArticleIdList></Reference><Reference><Citation>Rafiq MK, Lee E, Bradburn M, et al. Creatine kinase enzyme level correlates positively with serum creatinine and lean body mass, and is a prognostic factor for survival in amyotrophic lateral sclerosis. Eur J Neurol. 2016;23:1071&#x2013;1078. doi: 10.1111/ene.12995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12995</ArticleId><ArticleId IdType="pubmed">27029589</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X-P, Wei Q-Q, Ou R-W, et al. Creatine kinase in the diagnosis and prognostic prediction of amyotrophic lateral sclerosis: a retrospective case-control study. Neural Regen Res. 2021;16:591&#x2013;595. doi: 10.4103/1673-5374.293159.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.293159</ArticleId><ArticleId IdType="pmc">PMC7996010</ArticleId><ArticleId IdType="pubmed">32985493</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito D, Hashizume A, Hijikata Y, et al. Elevated serum creatine kinase in the early stage of sporadic amyotrophic lateral sclerosis. J Neurol. 2019;266:2952&#x2013;2961. doi: 10.1007/s00415-019-09507-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09507-6</ArticleId><ArticleId IdType="pubmed">31456060</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai H, Cui L, Guan Y, et al. Correlation of creatine kinase levels with clinical features and survival in amyotrophic lateral sclerosis. Front Neurol. 2017;8:322. doi: 10.3389/fneur.2017.00322.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2017.00322</ArticleId><ArticleId IdType="pmc">PMC5494475</ArticleId><ArticleId IdType="pubmed">28717355</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai H, Cui L, Liu M, et al. Creatine kinase level and its relationship with quantitative electromyographic characteristics in amyotrophic lateral sclerosis. Clin Neurophysiol. 2018;129:926&#x2013;930. doi: 10.1016/j.clinph.2018.01.071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2018.01.071</ArticleId><ArticleId IdType="pubmed">29550653</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceccanti M, Pozzilli V, Cambieri C, et al. Creatine kinase and progression rate in amyotrophic lateral sclerosis. Cells. 2020;9:E1174. doi: 10.3390/cells9051174.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9051174</ArticleId><ArticleId IdType="pmc">PMC7291088</ArticleId><ArticleId IdType="pubmed">32397320</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu C-H, Allen K, Oei F, et al. Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis. Neurol Neuroimmunol Neuroinflamm. 2016;3:e244. doi: 10.1212/NXI.0000000000000244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000244</ArticleId><ArticleId IdType="pmc">PMC4897985</ArticleId><ArticleId IdType="pubmed">27308305</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed RM, Dupuis L, Kiernan MC. Paradox of amyotrophic lateral sclerosis and energy metabolism. J Neurol Neurosurg Psychiatry. 2018;89:1013&#x2013;1014. doi: 10.1136/jnnp-2018-318428.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318428</ArticleId><ArticleId IdType="pubmed">29735514</ArticleId></ArticleIdList></Reference><Reference><Citation>Swaminathan R, Ho CS, Donnan SPB. Body composition and plasma creatine kinase activity. Ann Clin Biochem. 1988;25:389&#x2013;391. doi: 10.1177/000456328802500411.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/000456328802500411</ArticleId><ArticleId IdType="pubmed">3214120</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray E, Thompson AG, Wuu J, et al. CSF chitinases before and after symptom onset in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2020;7:1296&#x2013;1306. doi: 10.1002/acn3.51114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51114</ArticleId><ArticleId IdType="pmc">PMC7448184</ArticleId><ArticleId IdType="pubmed">32666680</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Andersen PM, et al. Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol. 2018;84:130&#x2013;139. doi: 10.1002/ana.25276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25276</ArticleId><ArticleId IdType="pubmed">30014505</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinaki M, Mulder DW. Amyotrophic lateral sclerosis: relationship between serum creatine kinase level and patient survival. Arch Phys Med Rehabil. 1986;67:169&#x2013;171. doi: 10.1016/0003-9993(86)90064-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0003-9993(86)90064-x</ArticleId><ArticleId IdType="pubmed">3954579</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Calvo A, Bovio G, et al. Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study. JAMA Neurol. 2014;71:1134. doi: 10.1001/jamaneurol.2014.1129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.1129</ArticleId><ArticleId IdType="pubmed">25048026</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Q-Q, Chen Y, Chen X, et al. Prognostic nomogram associated with longer survival in amyotrophic lateral sclerosis patients. Aging Dis. 2018;9:965&#x2013;975. doi: 10.14336/AD.2017.1016.</Citation><ArticleIdList><ArticleId IdType="doi">10.14336/AD.2017.1016</ArticleId><ArticleId IdType="pmc">PMC6284758</ArticleId><ArticleId IdType="pubmed">30574410</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong M-L, Tan PF, Holbrook JD. Predicting functional decline and survival in amyotrophic lateral sclerosis. PLoS&#xa0;One. 2017;12:e0174925. doi: 10.1371/journal.pone.0174925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0174925</ArticleId><ArticleId IdType="pmc">PMC5390993</ArticleId><ArticleId IdType="pubmed">28406915</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q-F, Hu W, Xu L-Q, et al. Decreased serum creatinine levels predict short survival in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2021;8:448&#x2013;455. doi: 10.1002/acn3.51299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51299</ArticleId><ArticleId IdType="pmc">PMC7886033</ArticleId><ArticleId IdType="pubmed">33449454</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>